Krystal Biotech, Inc. (KRYS)
After hours: 04:01PM EDT
Chart Events
Performance Outlook
| Previous Close | 47.67 |
| Open | 48.84 |
| Bid | 48.73 x 800 |
| Ask | 67.15 x 800 |
| Day's Range | 47.40 - 49.85 |
| 52 Week Range | 40.04 - 87.29 |
| Volume | 156,608 |
| Avg. Volume | 117,975 |
| Market Cap | 1.082B |
| Beta (5Y Monthly) | 1.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.16 |
| Earnings Date | Aug 09, 2021 - Aug 13, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 98.43 |
- GlobeNewswire
Krystal Biotech Announces Virtual Presentation of Pre-clinical Data on KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency at ESGCT
PITTSBURGH, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present pre-clinical pharmacology data on its second genetic pulmonary disease candidate KB408, for the treatment of alpha-1 antitrypsin deficiency (AATD), at the upcoming European Society of Gene & Cell Therapy (ESGCT) Virtual Congress held October 19 – 22, 2021. AATD is a rare genetic disorder that predisposes aff
- GlobeNewswire
Krystal Biotech and GeneDx Announce Collaboration to Provide No-charge Genetic Testing for Patients with Suspected Dystrophic Epidermolysis Bullosa (DEB)
The Krystal Decode DEB™ program is designed to shorten time to accurate diagnosis and facilitate the delivery of optimal carePITTSBURGH and GAITHERSBURG, Md., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, and GeneDx, Inc., a leader in genomic analysis and a wholly-owned subsidiary of BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced a collaboration offering no-char
- GlobeNewswire
Krystal Biotech to Present at the Chardan 5th Annual Genetic Medicines Conference
PITTSBURGH, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced its participation in the Chardan Virtual 5th Annual Genetic Medicines Conference, taking place October 4-5, 2021. Krish Krishnan, Chairman and CEO at Krystal Biotech, will participate in a fireside chat, and Whitney Ijem, SVP, Strategy & Business Development, will join a panel discussion on the utility of non-traditional viral v
